Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

CAPItello-292

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

MK-6482-043

PIKALO-1

Palbociclib and Pembrolizumab in Sarcoma

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

KANDELA-302

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

reaINAVO

TAPUR

EvoPAR-BR01

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

CYCAD-1

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

KAT6

Study of INCB123667 in Subjects With Advanced Solid Tumors

PALAVY

PAveMenT

SIRI

CAPTUR

SPARCC

Morpheus-panBC

SNV4818 in Participants With Advanced Solid Tumors

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Tazemetostat and Palbociclib With CPX-351for R/R AML

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

ELEVATE

Combined Immunotherapies in Metastatic ER+ Breast Cancer

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Study of AVZO-021 in Patients With Advanced Solid Tumors

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

DARE

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

APEAK

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Pilot Trial for Treatment of Recurrent Glioblastoma

COPS-01

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

PLATFORM Study of Precision Medicine for Rare Tumors

PALMARES-2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

TRAK-ER

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib